Precision medicine using patient-derived organoid of pancreatic cancer

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K07957
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 53010:Gastroenterology-related
• Research Institution: The University of Tokyo
• Principal Investigator: Saito Tomotaka 東京大学, 医学部附属病院, 助教 (10815781)
• Co-Investigator(Kenkyū-buntansha): 宮林 弘至 東京大学, 医学部附属病院, 助教 (50634961) ; 伊地知 秀明 東京大学, 医学部附属病院, 講師 (70463841)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: 膵癌 / オルガノイド / 個別化医療

Outline of Final Research Achievements

The aim of this study was to establish a drug screening platform using patient-derived organoids (PDOs) from pancreatic cancer. We successfully established 30 PDOs from needle biopsy specimens of pancreatic cancer patients, and drug screening was conducted on 20 of these PDOs. Sensitivity to five drugs commonly used in pancreatic cancer treatment (gemcitabine, 5-fluorouracil (5-FU), irinotecan, oxaliplatin, and paclitaxel) was determined, revealing differences in drug sensitivity depending on the type of PDO. Additionally, screening of molecular targeted drugs was performed on three PDOs, yielding similar results. This research is believed to contribute to the development of novel therapeutic strategies for the challenging cancer, pancreatic cancer. Further studies are warranted for potential clinical applications in the future.

Free Research Field

膵癌

Academic Significance and Societal Importance of the Research Achievements

膵癌は難治癌であり、効果的な治療戦略の開発が望まれる。本研究では膵癌患者より得られた検体からオルガノイドを樹立し、薬剤感受性を調べることで、治療戦略に役立てるプラットフォーム作成を目的とした。オルガノイドを30株樹立に成功し、そのうちの20株に対して薬剤試験を施行可能であり、有用な結果を得た。今後、臨床応用にむけてさらなる研究が望まれる。